Tumor Track

The Tumor Track will highlight new treatment options for glioma, metastases, and sellar/parasellar disease including neuro-oncology, surgery, imaging, radiation and systemic therapies that are aimed to improve patient outcomes. Sessions will feature the latest advances in state-of-the-art care for practicing clinicians treating patients with brain tumors. Cutting-edge topics in precision medicine, including genetic, translational, clinical research, trials and innovation will also be featured. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care.

Participants will leave with up-to-date, practical information which will have immediate clinical application, as well as technical and scientific background on the current state, and where the latest scientific advances may take the field.

Omar Arnaout, MD

Assistant Professor of Neurosurgery,
Harvard Medical School
Department of Neurosurgery
Brigham and Women’s Hospital

Wenya Linda Bi, MD, PhD

Assistant Professor of Neurosurgery,
Harvard Medical School
Department of Neurosurgery
Brigham and Women’s Hospital

Timothy R. Smith, MD, PhD, MPH 

Assistant Professor of Neurosurgery,
Harvard Medical School
Department of Neurosurgery
Brigham and Women’s Hospital

Highlighting new treatment options aimed at improving patient outcomes for glioma, metastases, and sellar/parasellar disease including:

• Neuro-oncology
• Surgery
• Imaging
• Radiation
• Systemic Therapies

• What does the neurooncologist want from the neurosurgeon?
• Microneurosurgery and glioma outcomes
• Impact of resection for gliomas
• The many colors of stereotactic biopsy for high-grade glioma
• Awake mapping for gliomas: setting a standard?
• Resting state fMRI for safe resection of eloquent gliomas
• Trailing the infiltrating disease: surgical adjuncts for glioma resection
• Implantable devices for high-grade glioma: back to the future?
• The role of conventional treatment for high-grade glioma
• The merits of clinical trials for high-grade glioma

• Treatment stratagies for aggressive pituitary adenomas
• Craniopharyngioma – Radical vs subtotal resection
• The Best Treatment for Rathke Cleft Cysts
• Post-radiation hypopituitarism and long term complications after RT to the sellar region
• Sinonasal Malignancies: When to Operate
• Sinonasal Malignancies: When Not to Operate
• Treatment of Adenoid Cystic Carcinoma
• Transpalpeberal Approach
• Tuberculum Meningioma
• Tuberculum Meningioma – endonasal
• Repair of Lateral Sphenoid Recess Encephaloceles

• Brain Mets 2020
• How Melanoma Treatment Transformed Cancer Care
• The Future of Lung Cancer Treatment
• Can we improve on what we have already done in breast cancer treatment?
• Leptomeningeal Disease: End of the Line?
• Approaches for Difficult Locations
• Brainstem Metastasis: Minimally Invasive Approaches
• SRS: The More the Merrier?
• The LITT at the end of the tunnel
• Complications and Pseudoprogression

• How Innovations Transform Neurosurgery
• Innovation in Clinical Trial Design & Interpretation
• From idea to scientific validation to FDA approval
• Commercializing Treatment
• Opportunities for the intraoperative scientist
• Natural vs Artificial Intelligence
• Benign Tumor Molecular Profile
• Innovation without Technology
• Digital Phenotyping

Nathalie Y.R. Agar, PhD
Department of Neurosurgery
Brigham and Women’s Hospital

Omar Arnaout, MD
Department of Neurosurgery
Brigham and Women’s Hospital

Antonio Aversa de Souto, MD
Department of Neurosurgery
University Hospital, Federal University of Rio de Janeiro, Brazil

Mark M. Awad, MD, PhD
Department of Medical Oncology
Dana-Farber Cancer Institute

Tracy T. Batchelor, MD
Department of Neurology
Brigham and Women’s Hospital

Mark Bernstein, MD
Department of Neurosurgery
Toronto Western Hospital

Wenya Linda Bi, MD, PhD
Department of Neurosurgery
Brigham and Women’s Hospital

Frederick A. Boop, MD
Department of Neurosurgery
Semmes Murphey Clinic

Henry Brem, MD
Department of Neurosurgery
Johns Hopkins University Hospital

Kaisorn Chaichana, MD
Department of Neurosurgery
Mayo Clinic, Jacksonville

Veronica L. Chiang, MD
Department of Neurosurgery
Yale University

Michael R. Chicoine, MD
Department of Neurosurgery
Washington Univeristy in St. Louis

Hugues Duffau, MD, PhD
Department of Neurosurgery
Montpellier University Medical Center, France

William B. Gormley, MD, MBA, MPH
Department of Neurosurgery
Brigham and Women’s Hospital

Federica Guaraldi, MD, PhD
Department of Endocrinology
IRCCS Istituto delle Scienze Neurologiche di Bologna

Constantinos G. Hadjipanayis, MD, PhD
Department of Neurosurgery
Mount Sinai Beth Israel Hospital

Melanie Hayden Gephart, MD, MAS
Department of Neurosurgery
Stanford University Medical Center

Frederick F. Lang, MD
Department of Neurosurgery
MD Anderson Cancer Center

Edward R. Laws, Jr., MD
Department of Neurosurgery
Brigham and Women’s Hospital

Michael T. Lawton, MD
Department of Neurosurgery
Barrow Neurological Institute

Nancy U. Lin, MD
Department of Medical Oncology
Dana-Farber Cancer Institute

Peter Nakaji, MD
Department of Neurosurgery
University of Arizona

Rifaquat M. Rahman, MD
Department of Radiation Oncology
Dana-Farber Cancer Insititute

Shaan M. Raza, MD
Department of Neurosurgery
MD Anderson Cancer Center

R. Michael Scott, MD
Department of Neurosurgery
Boston Children’s Hospital

Khalid Shah, MS, PhD
Department of Neurosurgery
Brigham and Women’s Hospital

Jason P. Sheehan, MD, PhD
Department of Neurosurgery
University of Virginia

Timothy R. Smith, MD, PhD, MPH
Department of Neurosurgery
Brigham and Women’s Hospital

Shyam K. Tanguturi, MD
Department of Radiation Oncology
Dana-Farber Cancer Insititute

Ugur Ture, MD
Department of Neurosurgery
Yeditepe University Hospital, Turkey

Ravi Uppaluri, MD, PhD
Department of Head and Neck Surgery
Dana-Farber Cancer Institute

Patrick Y. Wen, MD
Department of Neuro-Oncology
Dana-Farber Cancer Institute

Gabriel Zada, MD
Department of Neurosurgery
University of Southern California